Explain How Seebri and Utibron Stack Up Against Other Inhalers for COPD

February 2016

Two new glycopyrrolate-containing bronchodilators, Seebri (SEE-bree) and Utibron (YOO-tee-bron) Neohalers, will jostle for a place in the COPD market.

Consider these inhalers as me-too drugs.

Think of the single-agent glycopyrrolate (Seebri) as similar to tiotropium (Spiriva), aclidinium (Tudorza), or umeclidinium (Incruse)...and the indacaterol/glycopyrrolate combo (Utibron) as similar to umeclidinium/vilanterol (Anoro) or tiotropium/olodaterol (Stiolto).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Anticoagulants Don't Delay Restarting Anticoagulation in Atrial Fib Patients After GI Bleeding
Transitions of Care Prevent Med-Related Problems to Reduce Heart Failure Readmissions
Diabetes Caution about ketoacidosis, UTIs, and other serious ADRs with the SGLT2s
Hyperkalemia Suggest Low-Cost Treatments for High Potassium
MedGuides Know When to Give Hospitalized Patients MedGuides
Fall Risk Caution About Falls with SELECTIVE Alpha-blockers
New Drugs Don't Jump to Belbuca Before Non-Opioids for Chronic Pain
New Drugs Explain How Seebri and Utibron Stack Up Against Other Inhalers for COPD
Women's Health Don't Shun All SSRIs During Pregnancy
Hazardous Meds Avoid Crushing Fluconazole Tablets
Anesthesia Stick With Neostigmine for Most Neuromuscular Blockade Reversal

Explain How Seebri and Utibron Stack Up Against Other Inhalers for COPD

Get unlimited access through an Enterprise license

Table of Contents